Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

NCT02648477 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Estrogen Receptor Negative
Estrogen Receptor Positive
HER2/Neu Negative
Progesterone Receptor Negative
Progesterone Receptor Positive
Stage IV Breast Cancer
Triple-Negative Breast Carcinoma

Interventions

DRUG: Anastrozole
DRUG: Doxorubicin Hydrochloride
DRUG: Exemestane
OTHER: Laboratory Biomarker Analysis
DRUG: Letrozole
BIOLOGICAL: Pembrolizumab

Sponsor

City of Hope Medical Center

Collaborators

[object Object]
[object Object]